Rocket Pharmaceuticals has received the green light from the US Food and Drug Administration (FDA) to resume its pivotal Phase II Danon disease gene therapy trial, according to a recent report in Clinical Trials Arena. This development marks a significant step for both Rocket and the broader field of rare disease therapeutics, as Danon disease currently has no approved treatments and represents a critical unmet medical need.
Danon disease is a rare, inherited disorder caused by mutations in the LAMP2 gene. It leads to severe cardiac, skeletal muscle, and cognitive complications, often resulting in early death, especially among male patients. Rocket Pharmaceuticals is developing RP-A501, an investigational gene therapy designed to deliver a functional copy of the LAMP2B gene to patients’ heart cells, potentially correcting the underlying genetic defect.
Earlier this year, Rocket’s trial was paused due to a reported patient death, prompting a thorough safety review by the FDA. The company worked closely with regulators to address safety concerns, enhance monitoring protocols, and implement risk mitigation strategies. These included refined patient selection criteria, updated dosing regimens, and more intensive follow-up procedures to ensure patient safety throughout the trial.
With the FDA’s decision to lift the clinical hold, Rocket can now relaunch the Phase II trial and continue evaluating RP-A501’s safety and efficacy. The therapy uses an adeno-associated viral (AAV) vector to deliver the gene directly to cardiac tissue, aiming to restore proper cellular function and halt or reverse disease progression.
Danon disease is a devastating condition with rapid progression and high mortality, particularly in adolescent and young adult males. Symptoms include cardiomyopathy (heart muscle weakness), skeletal muscle problems, and learning difficulties. Most affected males require heart transplants in their teens or twenties, underscoring the urgent need for new therapies.
The FDA’s approval to resume clinical investigation is seen as a vote of confidence in Rocket’s revised safety measures and the potential for gene therapy to transform Danon disease treatment. If successful, RP-A501 could become the first approved therapy for this disorder, offering hope to patients and families who currently have very limited options.
Rocket Pharmaceuticals expressed gratitude for the FDA’s guidance and the collaboration that enabled the redesign and restart of the trial. The company reaffirmed its commitment to advancing the science of gene therapy while maintaining the highest safety standards.
